Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?

摘要: Small cell lung cancer (SCLC) is an aggressive form of cancer, which represents 13% all cases and strongly associated with cigarette smoking. The survival SCLC patients dismal has not greatly improved in the last 20 years, despite advances chemotherapy regimens a better understanding biology. development resistance to metastasis are commonly recognized as important causes poor clinical outcome SCLC. Targeting receptor tyrosine kinase (RTK) signalling attractive approach develop new drugs for SCLC, view accumulating data demonstrating that polypeptide growth factors play key role driving proliferation, chemoresistance metastasis. insulin-like factor-I (IGF-IR), c-Kit, vascular endothelial factor (VEGFR) epidermal (EGFR) have been identified potential drug targets Moreover, downstream mediators RTKs, such phosphoinositide 3-kinase (PI3K)/Akt mammalian target rapamycin (mTOR) may also represent candidate molecules anti-cancer therapies Here we will review available concerning results RTK inhibitors trials undertaken investigate these compounds anti-tumour agents